J&J's Scios Unit Gets Subpoena for Natrecor

The U.S. attorney's office in Boston is requesting more information.
Publish date:

Johnson & Johnson's

(JNJ) - Get Report

Scios division received a subpoena from the U.S. attorney's office in Boston requesting more information related to a congestive heart failure drug.

The office is requesting documents related to the sales and marketing of the drug Natrecor. Johnson & Johnson says it's cooperating.

In May, the Food and Drug Administration sent out a letter notifying doctors of the drug's possible side effects, including compromised kidney function and possibly even death. Natrecor sales in the most recent quarter sank about 20%.